Advancedbiotechnology

Pharmacogenomics

Overview

Pharmacogenomics studies how genetic variation affects drug response: metabolism (CYP2D6, CYP2C19, TPMT), targets, and immune reactions (HLA-B57:01/abacavir, HLA-B15:02/carbamazepine). Poor vs ultrarapid metabolizers need different doses; testing prevents toxicity and failure. CPIC guidelines and FDA labels now cover 100+ drug-gene pairs; preemptive panel testing is the future.

Learning objectives

  • Explain CYP2D6 metabolizer phenotypes
  • Describe HLA-drug hypersensitivity examples
  • Explain TPMT/thiopurine dosing
  • Discuss implementation challenges

CYP metabolism

CYP2D6 metabolizes ~25% of drugs (antidepressants, opioids, tamoxifen): poor metabolizers (no function) risk toxicity; ultrarapid metabolizers (gene duplications) get no effect or, with codeine, morphine overdose in children. CYP2C19 affects clopidogrel activation: poor metabolizers need alternatives after stenting.

Codeine tragedy

CYP2D6 ultrarapid-metabolizer children given codeine made lethal morphine levels: FDA boxed warning, PGx in action.

HLA hypersensitivity

HLA-B57:01 + abacavir -> hypersensitivity syndrome (screening eliminated it). HLA-B15:02 + carbamazepine -> Stevens-Johnson syndrome in Southeast Asians (screening standard there). These are immune, not metabolic: the drug alters HLA-presented peptides.

Ancestry-specific alleles

HLA risk alleles concentrate in ancestries: testing must follow the patient's background.

TPMT and thiopurines

TPMT methylates thiopurines (azathioprine, 6-MP for leukemia/IBD): poor metabolizers suffer fatal myelosuppression on standard doses. Genotype-guided dosing is a textbook PGx success: test first, dose safely. NUDT15 matters additionally in Asians.

Test before thiopurines

Guidelines mandate TPMT/NUDT15 testing: the clearest 'genotype or harm' case in medicine.

Implementation

CPIC guidelines translate genotypes to prescribing; FDA labels include PGx for 100+ drugs; preemptive panels (tested once, used for life) beat reactive testing. Barriers: clinician education, EHR integration, reimbursement, and evidence thresholds for each pair.

Test once, use for life

Germline PGx variants never change: preemptive panels amortize one test across decades of prescribing.

Key points

  • CYP2D6/CYP2C19 variation alters drug activation and clearance
  • HLA alleles predict severe immune drug reactions (abacavir, carbamazepine)
  • TPMT testing prevents thiopurine toxicity
  • CPIC guidelines + preemptive panels are bringing PGx to the clinic

Common misconceptions

✗ Myth: Pharmacogenomics means drugs designed for your DNA.

✓ Truth: Mostly it means dosing/selecting existing drugs by genotype; truly bespoke drugs are rare.

✗ Myth: One gene explains each drug response.

✓ Truth: Response is polygenic plus environmental; single genes dominate only the strongest pairs.

Practice questions

Q1. CYP2D6 ultrarapid metabolizers given codeine risk
  1. No effect
  2. Morphine toxicity from rapid conversion
  3. Allergy
  4. Nothing
Answer: B.

Excess conversion to morphine caused pediatric deaths: boxed warning.

Q2. HLA-B*57:01 screening prevents hypersensitivity to
  1. Penicillin
  2. Abacavir
  3. Aspirin
  4. Insulin
Answer: B.

Prospective screening eliminated abacavir hypersensitivity.

Q3. TPMT testing before thiopurines prevents
  1. Liver growth
  2. Fatal myelosuppression in poor metabolizers
  3. Hair loss only
  4. Nothing
Answer: B.

Poor metabolizers accumulate toxic thioguanine nucleotides.

Click a question to reveal the answer and explanation.

Frequently asked questions

Why does tamoxifen need CYP2D6?

Tamoxifen is a prodrug activated by CYP2D6 to endoxifen: poor metabolizers get less benefit.

What is the CPIC?

Clinical Pharmacogenetics Implementation Consortium: writes genotype-to-prescription guidelines.

Do PGx variants change over life?

Germline variants don't; but phenoconversion (drug interactions, disease) can override genotype.